– Vepdegestrant is the first PROTAC degrader to demonstrate clinical benefit in a Phase 3 trial – ...

Cancer is a diagnosis that no one wants to hear. Anyone who has survived cancer themselves or who has watched a loved one manage the disease would likely shudder at the word itself. While we can do ...

(Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in three upcoming investor ...

LMU researchers have shown that a particular type of immune cell acts more flexibly than previously thought—with the potential for new therapeutic approaches. As the researchers demonstrate ...

A new study suggests protein could help you lose fat without sacrificing muscle mass, offering hope for those looking to maintain muscle while shedding pounds. Read the full story here Radhika ...

Diffuse large B cell lymphoma (DLBCL) is a genetically highly heterogeneous disease. Yet, to date, the vast majority of patients receive standardized frontline chemo-immune-therapy consisting of an ...

To find out more, Sommars et al. studied the repressor BCL6 in mouse liver cells. The results revealed that BCL6 interacts with hundreds of the same genes as PPAR alpha. When the mice were eating, ...